Precision Medicine

A first-ever pediatric blue book has been developed as part of the fifth edition of the WHO Classification of Tumors series.

NAPLES, Florida — In this video, Anita Afzali, MD, MPH, FACG, discusses key takeaways from her presentation on precision therapy in IBD at the 2022 ACG/FGS Spring Symposium.

National Cancer Institute announced the launch of a program that offers molecular characterization of childhood cancers.

The FDA approved FoundationOne CDx as a companion diagnostic to guide treatment selection for certain patients with non-small cell lung cancer.

Use of genomics to guide treatment selection improved outcomes for certain patients with metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Racial and ethnic minority populations remain underrepresented in many precision oncology trials relative to their cancer incidence in the U.S., according to study results published in JAMA Network Open.

Charu Aggarwal, MD, MPH, spoke with Healio about a presentation she gave at this year’s Chemotherapy Foundation Symposium.

Karen M. Winkfield, MD, PhD, spoke with Healio about a lecture on precision medicine she gave at this year’s Chemotherapy Foundation Symposium.

Considerably fewer community oncology clinicians than academic clinicians use biomarker testing to guide discussions with patients with lung cancer, according to survey results.

In this episode, Lance Baldo, MD, discusses the use of MRD testing, T-cell receptor profiling, and how lessons from the COVID-19 pandemic will help shape the future of cancer vaccines.